ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, curcumin has demonstrated comparable efficacy to tyrosine kinase inhibitors (TKIs), such as imatinib, through downregulation of the BCR‐ABL oncoprotein (Wu et al. 2003).